Lawrence Schiller, MD, FACP, FACG Professor of Medicine Texas A&M College of Medicine Baylor University Medical Center Campus Dallas, TX
AMA PRA Category 1 Credit™ Medium
Mobile + Online on Univadis
Constipation is a common adverse effect resulting from opioid medications: an estimated 40% of patients receiving opioids to manage noncancer pain experience opioid-induced constipation (OIC). Unlike other adverse effects of opioids, such as nausea, the severity of OIC rarely diminishes over time and is often dose limiting. As a result, OIC can have a significant negative impact on activities of daily living and quality of life, and carries a substantial economic burden. This activity will examine strategies for addressing OIC in the primary care setting.
. Target Audience
This educational activity is designed to meet the needs of primary care clinicians, including physicians, NPs, and PAs, and other clinicians involved in the management of patients with OIC.
Upon completion of this educational activity, the participant should be able to:
Review the mechanisms of action of opioid analgesics and how they cause and/or contribute to constipation.
Describe strategies to assess for and accurately diagnose opioid-induced constipation (OIC).
Outline the indications for, efficacy, and safety of currently approved agents for OIC.
Describe optimal treatment protocols for patients with OIC.
Lawrence Schiller, MD, FACP, FACG, discloses the following conflicts of interest.
Speakers bureau: Allergan, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Inc.
Rick E. Ricer, MD, Professor Emeritus, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, CME Director, University of Cincinnati, has no conflicts of interest to disclose.
Deborah Cole, BS, Program Coordinator, University of Cincinnati, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.
The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity was developed through the joint providership of the University of Cincinnati and MCM Education.
Release date: June 27, 2017
Last review date: June 27, 2017
Expiration date: June 27, 2018
Please contact the University of Cincinnati Continuing Medical Education Department at firstname.lastname@example.org or call 513-558-7277.
For any technical issues or issues with your CME Certificate, please contact email@example.com. Commercial Support Statements
This activity is supported by educational grants from Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A, Inc. and Sucampo.
* Click "Start Program" and log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 80%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
©2017 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, Salix Pharmaceuticals, Takeda Pharmaceuticals U.S.A Inc., or Sucampo. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.